Prime Medicine falls on stock offering launch

** Shares of gene-editing firm Prime Medicine PRME.O down 9.4% to $3.55 in extended trading as it seeks equity raise

** Cambridge, Massachusetts-based PRME commences stock offering; deal size not disclosed

** TD Cowen and BMO are jt bookrunners

** Co has ~134.5 mln shares outstanding for ~$527 mln market cap, per LSEG data

** PRME shares on Weds finished up 2.3% at $3.92. Stock has gained ~59% in Jul, putting it up 34% YTD

** 8 of 12 analysts rate stock "strong buy" or "buy", rest rate "hold" and median PT is $8 - LSEG